DEPARTMENT OF HEALTH SERVICES

Division of Medicaid Services F-00081 (07/2021)

STATE OF WISCONSIN

Wis. Admin. Code § DHS 107.10(2)

FORWARDHEALTH PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR OPIOID DEPENDENCY AGENTS – BUPRENORPHINE

INSTRUCTIONS: Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Opioid Dependency Agents – Buprenorphine Instructions, F-00081A. Prescribers may refer to the Forms page of the ForwardHealth Portal at www.forwardhealth.wi.gov/WIPortal/Subsystem/Publications/ ForwardHealthCommunications.aspx?panel=Forms for the completion instructions.

Pharmacy providers are required to have a completed PA/PDL for Opioid Dependency Agents – Buprenorphine form signed and dated by the prescriber before calling the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or submitting a PA request on the Portal, by fax, or by mail. Prescribers and pharmacy providers may call Provider Services at 800-947-9627 with questions.

SECTION I – MEMBER INFORMATION									
1. Name – Member (Last, First, Middle Initial)									
2. Member ID Number	3. Date of Birth – Member								
SECTION II – PRESCRIPTION INFORMATION									
4. Drug Name	5. Dru	g Strength							
6. Date Prescription Written	7. Refills								
8. Directions for Use									
9. Name – Prescriber									
10. Address – Prescriber (Street, City, State, Zip + 4 Code)									
11. Phone Number – Prescriber		12. National Provider Identifie	Provider Identifier – Prescriber						
SECTION III – CLINICAL INFORMATION (Required for al	I PA rec	uests.)							
13. Diagnosis Code and Description									
14. Is the member 16 years of age or older?			Yes		No				
15. Is the member taking any other opioids, tramadol, or call	risoprodo	ol?	Yes		No				
If yes, list the drug(s) taken and the dates they have been	en taken	in the space provided.							



PA/PDL for Opioid Dependency Agents – Buprenorphine F-00081 (07/2021)

Page 2 of 2

16. Is the member pregnant?				Yes	☐ No				
If yes, indicate the member's expected delivery date (mm/dd/ccyy).									
1									
SECTION IV – ADDITIONAL CLINICAL INFORMATION FOR NON-PREFERRED BUPRENORPHINE-NALOXONE DRUG REQUESTS (PA requests for non-preferred buprenorphine-naloxone drugs may not be submitted via STAT-PA.)									
17. Provide detailed clinical justification for prescribing a non-preferred buprenorphine-naloxone drug instead of buprenorphine-naloxone tablets, Suboxone film, and Zubsolv, including clinical information why the member cannot use buprenorphine-naloxone tablets, Suboxone film, and Zubsolv and why it is medically necessary that the member receive a non-preferred buprenorphine-naloxone drug instead of buprenorphine-naloxone tablets, Suboxone film, and Zubsolv.									
SECTION V - AUTHORIZED SIGNATU	JRE								
18. SIGNATURE – Prescriber		19. Date Signed							
SECTION VI – FOR PHARMACY PROVIDERS USING STAT-PA									
20. National Drug Code (11 Digits) 21. Days' Supply R			equested (Up to 18	3 Days)					
22. National Provider Identifier									
23. Date of Service (mm/dd/ccyy) (For STAT-PA requests, the date of service may be up to 31 days in the future or up to 14 days in the past.)									
24. Place of Service									
25. Assigned PA Number									
26. Grant Date	27. Expiration Date		28. Number of Days Approved						
SECTION VII – ADDITIONAL INFORM	ATION	<u>'</u>							
29. Include any additional information in need for the drug requested may be		dditional diagnostic a	nd clinical informati	ion expl	aining the				